entertainment -WSS

entertainment

author：fashion 2025-09-29 00:27:14 - browse：888

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Crowdfunding for medical bills sidesteps core problem, author says

explore

WSS

Wellcome Trust names Røttingen as its new CEO

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

European regulators consider appeal over Amylyx ALS drug

As billionaires fund anti

STAT Readout Newsletter: Today in biotech, life science news

Empower primary care with adequate payments and technology

entertainment

entertainment

leisure time

How one medical school became remarkably diverse

As billionaires fund anti

As demand for Covid shots wanes, Moderna seeks its next success

Nick Jonas talks about managing diabetes along with his career

ChatGPT in medicine: STAT answers readers' burning questions

Life sciences deals on track to hit lowest point since 2017

Affirmative action in medical school literally saved lives

How doctors and nurses shape Google's AI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

European regulators recommend Amylyx's ALS drug be rejected

knowledge

Bernie Sanders bashes nonprofit hospitals over their tax breaks

PBM executives asked to testify by House panel

Black vets could get higher VA benefits if race not used in lung test

PBM executives asked to testify by House panel

Bernie Sanders bashes nonprofit hospitals over their tax breaks

AltruBio raises $225 million to develop ulcerative colitis drug

Wikipedia

hotspot

explore

knowledge